

CSL LTD.

ISIN: AU000000CSL8 WKN: CSL Asset Class: Stock

Company

2023/06/07 08:10:31



Price
308.86
AUD

Difference ▲
0.37%(1.14)



Contact Details

CSL LTD. Tel: +61-3-9389-1911
 -- Fax: +61-3-9389-1434
 45 Poplar Road Web: <http://www.csl.com.au>
 3052 Parkville E-mail: media@csl.com.au

Company Profile

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring and CSL Seqirus. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The CSL Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

Financial figures, Fiscal year: from 01.07. to 30.06.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	23,937,613,000		9,843,090,000		9,362,672,000	
Common stock capital		-		-		-
Fixed assets	17,283,938,000		14,341,924,000		13,098,620,000	
Equity capital of a company		21,199,011,000		11,163,902,000		9,480,610,000
Cash and cash equivalents	15,176,906,000		2,409,324,000		1,734,785,000	
Accrued liabilities		422,744,000		525,074,000		565,286,000
Other assets	-		-		-	
Current liabilities		10,336,944,000		4,133,999,000		3,110,384,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		9,685,595,000		8,837,562,000		9,811,909,000
Different income		-		-		-
Other liabilities		779,030,000		596,869,000		325,054,000
Total assets	41,221,551,000	41,221,551,000	24,185,014,000	24,185,014,000	22,461,292,000	22,461,292,000

Balance notes

	2022	2021	2020
Accounting standard	IFRS	IFRS	IFRS
Employees	30,000	25,000	27,000
Equity ratio	51.43%	46.16%	42.21%
Debt-equity ratio	94.45%	116.64%	136.92%

Others

	2022	2021	2020
Tax Expense Rate	18.88%	19.85%	18.28%

CSL LTD.

ISIN: AU000000CSL8 WKN: CSL Asset Class: Stock

Income statement

	2022	2021	2020
Turnover	14,469,426,000	13,761,477,000	13,575,278,000
Net income	3,109,111,000	3,183,882,000	3,136,313,000
EBIT	2,512,563,579	2,594,142,551	2,513,947,629
Operating income before taxes	3,832,920,000	3,972,278,000	3,837,714,000
Cash Flow	3,624,837,000	4,855,454,000	3,711,814,000
Net interest income	-240,626,000	-233,529,000	-238,076,000
Research and development expenses	1,594,338,000	1,342,458,000	1,375,055,000
Income taxes	723,809,000	788,396,000	701,400,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	297,491	339,523	310,120

Board of Directors

Brian McNamee	Chairman of Supervisory Board
Andrew Cuthbertson	Member of Supervisory Board
Duncan Maskell	Member of Supervisory Board
Megan Clark	Member of Supervisory Board
Alison Watkins	Member of Supervisory Board
Bruce Brook	Member of Supervisory Board
Carolyn Hewson	Member of Supervisory Board
Marie McDonald	Member of Supervisory Board

Members of Management Board

Paul Perreault	Chairman of Managing Board
Alan Wills	Member of Executive Committee
Bill Campbell	Member of Executive Committee
Bill Mezzanotte	Member of Executive Committee
Elizabeth Walker	Member of Executive Committee
Greg Boss	Member of Executive Committee
John Levy	Member of Executive Committee
Mark Hill	Member of Executive Committee
Paul McKenzie	Member of Executive Committee